1. Home
  2. RCS vs TECX Comparison

RCS vs TECX Comparison

Compare RCS & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PIMCO Strategic Income Fund Inc.

RCS

PIMCO Strategic Income Fund Inc.

HOLD

Current Price

$6.73

Market Cap

308.9M

Sector

Finance

ML Signal

HOLD

Logo Tectonic Therapeutic Inc.

TECX

Tectonic Therapeutic Inc.

HOLD

Current Price

$18.62

Market Cap

359.0M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
RCS
TECX
Founded
1994
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
308.9M
359.0M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
RCS
TECX
Price
$6.73
$18.62
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$81.20
AVG Volume (30 Days)
141.1K
343.2K
Earning Date
01-01-0001
11-06-2025
Dividend Yield
10.12%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.51
$13.70
52 Week High
$6.31
$61.07

Technical Indicators

Market Signals
Indicator
RCS
TECX
Relative Strength Index (RSI) 43.12 50.48
Support Level $6.65 $17.79
Resistance Level $6.76 $19.12
Average True Range (ATR) 0.12 1.38
MACD 0.01 -0.24
Stochastic Oscillator 26.02 38.81

Price Performance

Historical Comparison
RCS
TECX

About RCS PIMCO Strategic Income Fund Inc.

PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with the objective.

About TECX Tectonic Therapeutic Inc.

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

Share on Social Networks: